I don’t think Pascal is going to be a handbrake on growth.
https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/
CSL’s newest director is into growth
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$262.59 |
Change
-7.660(2.83%) |
Mkt cap ! $119.4B | |||
| Open | High | Low | Value | Volume |
| $266.61 | $267.63 | $262.59 | $324.9M | 1.231M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 182 | $262.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $262.59 | 292 | 1 |
View Market Depth
| Last trade - 16.10pm 26/02/2021 (20 minute delay) ? |
 (live)
|
|||||
|
Last
$262.59 |
Change
-7.660 ( 3.18 %) |
||||
| Open | High | Low | Volume | ||
| $266.54 | $267.60 | $262.59 | 91637 | ||
| Last updated 16.10pm 26/02/2021 (live) ? | |||||
| CSL (ASX) Chart |